Toviaz (Fesoterodine) — Competitive Intelligence Brief

Toviaz (Fesoterodine) (Toviaz (Fesoterodine)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic M3 receptor antagonist. Area: Urology.

marketed Muscarinic M3 receptor antagonist M3 muscarinic acetylcholine receptor Urology Small molecule

Target snapshot

Toviaz (Fesoterodine) (Toviaz (Fesoterodine)) — Weill Medical College of Cornell University. Fesoterodine is a muscarinic M3 receptor antagonist that relaxes bladder smooth muscle to reduce urinary incontinence and overactive bladder symptoms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Toviaz (Fesoterodine) TARGET	Toviaz (Fesoterodine)	Weill Medical College of Cornell University	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor
salbutamol + ipratropium bromide nebules	salbutamol + ipratropium bromide nebules	Imperial College London	marketed	Combination bronchodilator (beta-2 agonist + anticholinergic)	Beta-2 adrenergic receptor (salbutamol); M3 muscarinic acetylcholine receptor (ipratropium)
Oxybutynin chloride, extended-release	Oxybutynin chloride, extended-release	US Department of Veterans Affairs	marketed	Anticholinergic agent	M3 muscarinic acetylcholine receptor
Spiriva HandiHaler	Spiriva HandiHaler	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	marketed	Long-acting muscarinic antagonist (LAMA)	M3 muscarinic acetylcholine receptor
Detrol LA	Detrol LA	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic acetylcholine receptors
Drug: ipratropium (AtroventTM)	Drug: ipratropium (AtroventTM)	AstraZeneca	marketed	Anticholinergic bronchodilator	M3 muscarinic acetylcholine receptor
Anoro® Ellipta®	Anoro® Ellipta®	AstraZeneca	marketed	Long-acting beta-2 agonist / Long-acting muscarinic antagonist (LABA/LAMA combination)	Beta-2 adrenergic receptor and M3 muscarinic acetylcholine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic M3 receptor antagonist class)

1. Astellas Pharma Inc · 2 drugs in this class
2. Barrie Urology Associates · 1 drug in this class
3. National Taiwan University Hospital · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Seattle Urology Research Center · 1 drug in this class
6. Weill Medical College of Cornell University · 1 drug in this class